Your browser doesn't support javascript.
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.
Martinez, David R; Schäfer, Alexandra; Leist, Sarah R; Li, Dapeng; Gully, Kendra; Yount, Boyd; Feng, Joy Y; Bunyan, Elaine; Porter, Danielle P; Cihlar, Tomas; Montgomery, Stephanie A; Haynes, Barton F; Baric, Ralph S; Nussenzweig, Michel C; Sheahan, Timothy P.
  • Martinez DR; Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: david.rafael.martinez@gmail.com.
  • Schäfer A; Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Leist SR; Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Li D; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Gully K; Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Yount B; Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Feng JY; Gilead Sciences, Inc., Foster City, CA, USA.
  • Bunyan E; Gilead Sciences, Inc., Foster City, CA, USA.
  • Porter DP; Gilead Sciences, Inc., Foster City, CA, USA.
  • Cihlar T; Gilead Sciences, Inc., Foster City, CA, USA.
  • Montgomery SA; Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Baric RS; Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Nussenzweig MC; The Rockefeller University, New York, NY, USA; The Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Sheahan TP; Department of Epidemiology, READDI Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: sheahan@email.unc.edu.
Cell Rep ; 36(4): 109450, 2021 07 27.
Article in English | MEDLINE | ID: covidwho-1306890
ABSTRACT
Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Monoclonal Type of study: Prognostic study Topics: Variants Limits: Animals / Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Monoclonal Type of study: Prognostic study Topics: Variants Limits: Animals / Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article